11 results about "Cycloastragenol" patented technology

The invention discloses a composite microneedle with bacterial outer membrane vesicles loaded with active ingredients as well as a preparation method and application of the composite microneedle. The composite microneedle is prepared from the bacterial outer membrane vesicles and the active ingredients loaded in the bacterial outer membrane vesicles, the bacterial outer membrane vesicles are derived from mucus eubacterium, the active ingredient is cycloastragenol, and the composite microneedle has a transdermal delivery function and delivers the active ingredient to a target tissue in a targeted manner. The method comprises the following steps: firstly, encapsulating cycloastragenol into mucus eubacterium outer membrane vesicles through a co-incubation or active drug loading technology to form a composite nano-carrier; the EL-OMVs-CAG compound prepared by the invention has good biocompatibility and blood brain barrier penetrating ability, and can target a central nervous system, regulate the activity of microglial cells, inhibit neuroinflammatory response and reduce synaptic loss and neuronal apoptosis in a hippocampal region, so that cognitive function impairment caused by operation and anesthesia is improved.

According to the application, an acute hypoxia animal model is established through a plateau low-pressure oxygen cabin, and the effect of cycloastragenol on prevention of acute hypoxia movement stress mice after pretreatment is evaluated. It is found that cycloastragenol after pretreatment has no adverse effect on the body, the exercise performance of mice can be improved, the exercise time can be prolonged, and gastrocnemius muscle and myocardial tissue damage can be improved. Accumulation of LAC in serum after exhaustive exercise can be remarkably reduced, accumulation of a metabolite BUN is reduced, the activity of antioxidant enzyme T-SOD in the serum is remarkably improved, and accumulation of a lipid peroxidation product MDA in the serum is reduced. The cycloastragenol can reduce the content of inflammatory factors IL-6 and TNF-alpha in serum, improve the level of Ca < 2 + >-Mg < 2 + >-ATP enzyme and Na < + >-K < + >-ATP enzyme in gastrocnemius muscle, regulate energy metabolism and improve energy supply efficiency.

The application provides a preparation method of cycloastragenol and relates to the technical field of biology.The preparation method of the cycloastragenol comprises the following steps: preparing a mixed solution of astragaloside, xylosidase and GSM microbial agent, and preparing the cycloastragenol through a conversion reaction.The preparation method can realize 100% conversion of the astragaloside through the synergistic effect of the GSM microbial agent and the xylosidase, and the preparation method is simple and efficient, and the prepared cycloastragenol has high yield and high purity.

The invention discloses a process for preparing astragaloside through multi-strain fermentation. Through segmented biotransformation, by utilizing a segmented process that in-situ enzyme production of trichoderma reesei, aspergillus oryzae deacetylation and aspergillus niger step-by-step desugaring are carried out to directionally transform upstream saponin, and bacillus subtilis and candida are used for terminal modification, astragaloside is not subjected to continuous desugaring or ring opening to obtain cycloastragenol after being formed, and the yield of astragaloside is remarkably improved.

The invention discloses a method for directly cryopreserving pig ear edge tissues by cycloastragenol and application of cycloastragenol, and relates to the technical field of refrigeration or cryopreservation. On the basis of an existing refrigerating fluid formula, the concentration of DMSO is reduced, high-glucose DMEM is used for replacing DPBS, meanwhile, trehalose, cycloastragenol and the like are added, and a brand-new refrigerating fluid formula is provided. The method has the following advantages: 1) an unfreezing solution and an equilibrium solution do not need to be additionally prepared; the unfreezing method is easy to operate, only simple melting is needed, and the method is suitable for large-scale preservation. And 3) the tissue does not need to be subjected to complex pretreatment, and only the tissue needs to be simply cleaned. The method has the advantages that the method is suitable for field sampling, strict sterile conditions are not needed, the cell survival rate, the cell apoptosis rate, the mitochondrial membrane potential, the active oxygen, the cell proliferation rate and the like are not obviously different from those of cells cultured from fresh tissue, and the volume of the supported cryopreserved tissue is the maximum cryopreserved volume in the cryopreserved pig tissue which can be found at present.

The invention relates to the technical field of drugs for delaying senescence of lens cells, and particularly discloses a pharmaceutical composition for delaying senescence of lens cells and application thereof, the pharmaceutical composition comprises 0.05-0.1 wt% of cycloastragenol ester derivatives, 0.1-5 wt% of a solubilizer, 1.0-10.0 wt% of a cosolvent, 0.5-2.0 wt% of an osmotic pressure regulator, 0.01-0.5 wt% of a buffer salt, 0.001-0.05 wt% of a preservative, and the balance of water for injection; wherein the cycloastragenol ester derivative is cycloastragenol-3-acetate, and the structural formula of the cycloastragenol ester derivative is shown in Cycloastragenol-3-acetate is applied to delaying senescence of lens cells, compared with a parent compound cycloastragenol, the esterified derivative has significantly enhanced fat solubility and cell membrane permeability, and under the same concentration, the ability of activating the telomerase activity of lens epithelial cells is significantly superior to that of cycloastragenol; stronger biological activity potential is shown.

The invention relates to the field of biological medicine, and discloses application of cycloastragenol in preparation of a medicine for treating lung adenocarcinoma combined anxiety depression. According to the application, cycloastragenol is found to relieve anxiety and depression symptoms by adjusting the level of corticosterone and other stress hormones; the anti-tumor immune response is enhanced by inhibiting the depletion of CD8 + T cells; and the anti-tumor capability of the CD8 + T cells is recovered by inhibiting the expression of Fabp5, so that a new idea and a potential drug choice are provided for clinical treatment of lung adenocarcinoma combined anxiety depression.

The invention provides a proliferation culture medium for long-term stable passage of bovine-derived cells, a method for promoting long-term stable passage of bovine-derived cells and application of the proliferation culture medium. The proliferation culture medium comprises the following components: a complete culture medium, cycloastragenol and metformin hydrochloride. Researches show that the proliferation culture medium can make bovine embryo fibroblasts (BFFs) break through the proliferation limit in the in-vitro subculture process, a continuous cell line is formed, and production of cell culture meat products with excellent quality is facilitated. The culture medium provided by the invention can support continuous passage of BFFs to 145 generations, and the cell type of the bovine embryo fibroblast cell line subjected to passage to 145 generations is unchanged, so that the culture medium has the advantage of long-term stable passage. Through induction of the proliferation culture medium, the BFFs can break through aging limitation, long-term stable passage (more than or equal to 100 generations) is realized, the waveform protein positive rate of more than 90% is maintained, the requirement of mass production of cell culture meat on the cell number is met, and the proliferation culture medium has a very wide application prospect.

The invention discloses a preparation method and application of cycloastragenol, and the method comprises the following steps: preparation of an astragaloside solution: mixing a hydrogen bond donor and a hydrogen bond acceptor according to a preset molar ratio, controlling the reaction within a first preset temperature range to obtain a deep-eutectic solvent, heating the deep-eutectic solvent to a second preset temperature, adding astragaloside powder, and stirring to obtain the astragaloside solution; an astragaloside solution is obtained; enzyme catalytic reaction: adding an astragaloside solution and beta-xylosidase into the buffer solution to carry out first-step catalytic reaction, then adding beta-glucosidase to carry out second-step catalytic reaction, and carrying out enzyme deactivation and filtration to obtain enzymatic hydrolysate; and separation and purification of cycloastragenol: adsorbing and separating the enzymatic hydrolysate by adopting macroporous adsorption resin, collecting eluent, and drying to obtain cycloastragenol powder. According to the method, solubilization of water-insoluble astragaloside, catalysis of biological enzymolysis and stabilization of active substances are realized by using the eutectic solvent, the enzymolysis conversion rate is high, the reaction time is shorter, and the method is suitable for large-scale mechanical production.

The invention discloses a primary tissue or organ-like cryopreservation solution which is prepared from dimethyl sulfoxide, dextran-20, primary cell antibiotics, Penicillin-streptomysin, bovine serum albumin, insulin, transferrin, growth hormone, fibroblast growth factors, human platelet growth factors, bone morphogenetic protein 4, human epidermal growth factors, insulin-like growth factors and the balance of distilled water. The culture medium is prepared from a hepatocyte growth factor, L-glutamic acid, alanine, glycine, L-asparaginic acid, L-proline, serine, sodium pyruvate, glutamine, nicotinamide, N-acetylcysteine, beta-mercaptoethanol, sodium selenite, beta glycerophosphate, cycloastragenol, Y-27632, a DMEM (Dulbecco Modified Eagle Medium) basal culture medium and the like. After the cryopreserved tissue is recovered, the isolated culture of the primary cells can be normally carried out, the viability of the primary cells reaches 93%, and the survival rate of the recovered organoid reaches 92%.

This invention belongs to the field of biomedicine and anti-aging technology. It provides a cycloastragaloside-linker-pyrroloquinolinequinone conjugate as shown in general formula (I): CAG-L-PQQ (I), wherein CAG is a cycloastragaloside group, PQQ is a pyrroloquinolinequinone group, L is a linker selected from C2-C10 straight-chain or branched alkylene groups, optionally interrupted by heteroatoms, and both ends are connected by ester bonds. This invention also provides a method for preparing the compound, pharmaceutical compositions containing the compound, and its applications in delaying aging, extending telomere length, and repairing telomere damage. By selecting different linkers, the stability, water solubility, and release characteristics of the compound can be optimized. Through chemical coupling, the spatiotemporal release of cycloastragaloside and PQQ is achieved, and it is expected to exert a triple synergistic effect of telomerase activation, mitochondrial protection, and improved replication fidelity, showing broad application prospects.